EnprEMA Network Database.

The Enpr-EMA Network Database is a publicly searchable resource maintained by the European Medicines Agency that provides information on recognised paediatric research networks and clinical centres across Europe. The database allows researchers, sponsors and other stakeholders to identify networks with expertise in conducting paediatric clinical trials by searching according to therapeutic area, age group, geographical coverage and research capabilities. Each network profile includes information on research experience, scientific expertise, quality management systems, training capacity, public involvement and contact details, facilitating the identification of appropriate collaborators and trial sites. The database serves as a practical resource for building research partnerships and supporting the operational planning of multinational clinical trials.

Although established to support paediatric medicines development, the Enpr-EMA Network Database is highly relevant to rare disease clinical research. A large proportion of rare diseases present during childhood, and many rare disease trials depend on collaboration between specialised centres across multiple countries to achieve adequate recruitment and access disease-specific expertise. By enabling researchers to identify networks with recognised experience in paediatric clinical research, the database can facilitate site selection, investigator identification, partnership development and the establishment of multinational trial consortia. These are common requirements across paediatric and rare disease clinical trials, making the resource broadly applicable beyond its original paediatric focus.

For trial management, the Enpr-EMA Network Database supports efficient study implementation by helping investigators identify experienced research infrastructures capable of conducting complex paediatric and rare disease studies. It complements methodological and regulatory guidance by providing practical access to established clinical research networks, thereby strengthening collaboration, improving trial feasibility and supporting the successful delivery of multinational rare disease clinical trials.